Connect your AI

Evommune EVMN Gain (Loss) on Derivative Instruments, Net, Pretax

Gain (Loss) on Derivative Instruments, Net, Pretax at other companies

Black Stone MineralsBSM

-$64.55M-15.3%

indie Semiconductor, Inc.INDI

-$637K-6.0%

SM EnergySM

-$697M-4,000%

Alerus Financial CorporationALRS

$261K-9.7%

PegasystemsPEGA

$0+100%

Liberty GlobalLBTYB

$132.2M+180%

Other financials

Income statement

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:GainLossOnDerivativeInstrumentsNetPretax.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's gain (loss) on derivative instruments, net, pretax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evommune 's gain (loss) on derivative instruments, net, pretax?: Evommune (EVMN) reported gain (loss) on derivative instruments, net, pretax of $78.43K in Q1 2026.